TY - JOUR
T1 - Mortality and recurrence patterns of breast cancer patients diagnosed under a screening programme versus comparable non-screened breast cancer patients from the same population: Analytical survey from 2002 to 2012
AU - García Fernández, A.
AU - Chabrera, C.
AU - García Font, M.
AU - Fraile, M.
AU - Lain, J. M.
AU - Gónzalez, S.
AU - Corral, C.
AU - Torras, M.
AU - Torres, J.
AU - Teixido, M.
AU - Barco, I.
AU - López, R.
AU - Gónzalez, C.
AU - Pessarrodona, A.
AU - Giménez, N.
PY - 2014/1/1
Y1 - 2014/1/1
N2 - Breast cancer screening programmes seem to bring about significant benefits, including decreased mortality, although they may also have some drawbacks such as false-negative and false-positive results. This study aims to compare the clinical outcome of a group of patients undergoing a breast cancer screening programme with that of a synchronous non-screened group of patients matched for age and follow-up period. We studied basic characteristics of epidemiology, immunohistochemistry, loco-regional relapse, distant metastases, disease-free interval and overall and specific mortality. We compared 510 patients in the screened group with 394 non-screened patients, along the period of 2002-2012. Screening was applied on a target population of 49,847 and was based on double-projection, double-read mammograms. Two years were allowed per round. Overall participation for the five rounds considered was 75.2 %, with 86.5 % coverage, and a total cumulative population of 123,445. The non-participant women amounted 40,794. Tumour detection rate for the screened women was 3.8 per thousand (475/123,445), while the corresponding rate for non-participants was 9.4 per thousand (382/40,797). Incidence of luminal A subtype was 15 % higher in screened than that in non-screened patients (95 % confidence interval (CI) 8-22 %). Conversely, the triple-negative subtype was 6 % higher in the non-screened group (95 % CI 2-10 %). Incidence of breast conservative treatments and sentinel node biopsies was significantly higher in the screened group. Overall mortality was 2.6 times higher in non-screened than that in screened group (95 % CI 1.2-5.6) After 10 years of experience with our own screening programme, we believe that included patients receive a benefit versus comparable non-screened breast cancer patients, with acceptable benefit-risk relation. © 2013 International Society of Oncology and BioMarkers (ISOBM).
AB - Breast cancer screening programmes seem to bring about significant benefits, including decreased mortality, although they may also have some drawbacks such as false-negative and false-positive results. This study aims to compare the clinical outcome of a group of patients undergoing a breast cancer screening programme with that of a synchronous non-screened group of patients matched for age and follow-up period. We studied basic characteristics of epidemiology, immunohistochemistry, loco-regional relapse, distant metastases, disease-free interval and overall and specific mortality. We compared 510 patients in the screened group with 394 non-screened patients, along the period of 2002-2012. Screening was applied on a target population of 49,847 and was based on double-projection, double-read mammograms. Two years were allowed per round. Overall participation for the five rounds considered was 75.2 %, with 86.5 % coverage, and a total cumulative population of 123,445. The non-participant women amounted 40,794. Tumour detection rate for the screened women was 3.8 per thousand (475/123,445), while the corresponding rate for non-participants was 9.4 per thousand (382/40,797). Incidence of luminal A subtype was 15 % higher in screened than that in non-screened patients (95 % confidence interval (CI) 8-22 %). Conversely, the triple-negative subtype was 6 % higher in the non-screened group (95 % CI 2-10 %). Incidence of breast conservative treatments and sentinel node biopsies was significantly higher in the screened group. Overall mortality was 2.6 times higher in non-screened than that in screened group (95 % CI 1.2-5.6) After 10 years of experience with our own screening programme, we believe that included patients receive a benefit versus comparable non-screened breast cancer patients, with acceptable benefit-risk relation. © 2013 International Society of Oncology and BioMarkers (ISOBM).
KW - Breast neoplasms
KW - Mass screening
KW - Mortality
U2 - 10.1007/s13277-013-1260-7
DO - 10.1007/s13277-013-1260-7
M3 - Review article
SN - 1010-4283
VL - 35
SP - 1945
EP - 1953
JO - Tumor Biology
JF - Tumor Biology
IS - 3
ER -
